The Transitional Cell Carcinoma is a particularly unpleasant tumor of the urinary bladder which usually grows in the lower neck of the bladder causing a partial or complete obstruction to urination. The urethra (which carries urine outside the body) is affected in over half the patients diagnosed with Transitional Cell Carcinoma.
AMFR
- Autocrine motility factor receptor is detectable in the urine of patients with TCC. PMID: 7490884
CYFRA 21-1
- Urinary CYFRA 21-1 may be a useful marker for diagnosing transitional cell carcinoma. PMID: 9224298
MIB-1
- immunostaining in transitional cell carcinoma of the bladder correlated well with grade, stage, and clinical outcome. PMID: 10861439
NMP22
- a new marker in patients with transitional cell carcinoma. PMID: 10431409
- useful in differentiating subjects affected by TCC from subjects with no evidence of malignancy and may help in early diagnosis of TCC and in predicting recurrent even if low grade tumors especially if used in association with cytology and endoscopy. PMID: 10193018
- a promising urinary tumor marker for monitoring transitional cell carcinoma. PMID: 8808854
p53 and MIB-1
- Quantitative immunohistochemical evaluation of nuclear p53 and MIB-1 immunostaining inexpensively provides prognostic indicators in cases of TCC of the bladder. PMID: 9338472
Telomerase
- a potential marker of bladder transitional cell carcinoma in bladder washes. PMID: 9259615